Encompass Health’s Shrinking Valuation Disparity as Expansion and Competitive Edge Surpass Market Doubts

Encompass Health: Focused Growth and Strategic Positioning

Encompass Health has streamlined its operations to concentrate solely on inpatient rehabilitation hospitals (IRFs) after divesting its home health and hospice divisions in 2022. This strategic shift enables the company to dedicate its resources and expertise to a specialized area where clinical outcomes are paramount for success.

The company’s competitive advantage is rooted in its consistent record of clinical excellence. For six years running, Encompass Health has been recognized as "America's Most Awarded Leader in Inpatient Rehabilitation," with a record-setting 66 facilities earning this distinction in 2025. These awards, based on quality measures, expert evaluations, and patient satisfaction, reinforce the company’s strong reputation and brand trust. In healthcare, where referrals drive patient volume and payer relationships, such recognition directly supports business growth.

This trust is now translating into operational performance. In 2025, Encompass Health reported a 10.5% increase in revenue, a notable achievement for a mature healthcare provider. Management attributes this to a 6% rise in discharges and a more favorable patient mix, indicating both an increase in patient numbers and a shift toward more complex, higher-reimbursing cases. This blend of volume and quality underscores the company’s enduring competitive edge and positions it for sustained value creation.

Growth Outlook and Valuation: Assessing the Margin of Safety

Encompass Health’s growth plan is both clear and ambitious. The company aims to add 500 to 600 beds each year through new construction, acquisitions, and facility expansions, with a focus on entering new states and developing smaller hospitals to meet the needs of an aging population. The company’s operational results in 2025, including a 10.5% revenue increase driven by discharge growth and patient mix, support this strategy.

Despite these positive fundamentals, the market has responded negatively. The company’s stock has fallen 24% in the last 120 days and 10% in the past 20 days, now trading near its 52-week low of $92.77. This disconnect between business performance and share price presents a potential opportunity for value investors.

Analysts project a forward revenue growth rate of about 7.9%, which, when considered alongside the current valuation, results in a PEG ratio near 0.70. For a business with a strong competitive position, a PEG below 1.0 suggests the stock may be attractively valued, especially if growth remains consistent. With a leverage ratio of 1.9 times in 2025—expected to improve further—the company has the financial strength to support its expansion plans without excessive risk.

Absolute Momentum Long-only Strategy: Backtest Summary

• Entry Criteria: Buy when the 252-day rate of change is positive and the closing price is above the 200-day SMA.
• Exit Criteria: Sell when the closing price falls below the 200-day SMA, after 20 trading days, or if a take-profit of +8% or stop-loss of −4% is triggered.
• Backtest Results:
  • Strategy Return: 7.43%
  • Annualized Return: 4.96%
  • Maximum Drawdown: 14.74%
  • Profit-Loss Ratio: 1.23
  • Total Trades: 12 (6 wins, 6 losses; 50% win rate)
  • Average Hold: 13 days
  • Max Consecutive Losses: 3
  • Average Win: 6.47%
  • Average Loss: 4.8%
  • Best Trade: 15.79%
  • Worst Trade: 12.21%

The central question for investors is whether the current share price accurately reflects the risks to the company’s growth trajectory. Encompass Health faces challenges such as Medicare Advantage utilization and the impact of unit closures in early 2026. However, these are operational hurdles rather than existential threats. The real test is whether the company’s disciplined execution and competitive advantages can eventually drive a revaluation of the stock, offering a margin of safety at current levels.

Financial Strength and Capital Deployment

For value investors, a company’s financial resilience and capital allocation strategy are critical. Encompass Health’s balance sheet is robust, supporting its growth ambitions. At the end of 2025, the company reported a leverage ratio of 1.9 times, with expectations to reduce this to 1.8 times by the close of 2026. This conservative debt profile gives the company flexibility to pursue expansion without overextending financially.

In 2025, management allocated $527 million to growth capital expenditures, directly fueling the plan to add 500 to 600 beds annually. At the same time, Encompass Health returned value to shareholders through a $160 million share buyback and over $70 million in cash dividends. This balanced approach—investing in growth while rewarding shareholders—demonstrates a commitment to long-term value creation.

Operational efficiency has also improved significantly. The company cut premium labor costs in half compared to 2022, with a $21 million reduction from 2024 to 2025. These gains, achieved through centralized hiring and lower turnover, support stable margins and enhance returns on growth investments, showing that Encompass Health is not only expanding but also improving its operational quality.

In summary, Encompass Health stands on solid financial ground, with prudent capital allocation and rising operational efficiency. The company is well-positioned to execute its long-term strategy, and recent market pessimism may not fully reflect these strengths.

Risks and Industry Challenges

Despite its operational achievements, Encompass Health operates in a dynamic and challenging environment. Several ongoing risks could impact its growth and competitive position.

The most immediate concern is the evolving payer landscape. Medicare Advantage penetration is expected to reach nearly 17% by 2025, but growth in this segment slowed in the last quarter of the year. Since Medicare Advantage plans differ from traditional Medicare in utilization and reimbursement, slower growth could affect the company’s patient mix and margins.

Labor remains a persistent challenge. While premium labor costs were reduced by $21 million from 2024 to 2025, and halved since 2022, ongoing investment in talent is necessary. The healthcare labor market is competitive, and any increase in wage pressures or difficulty hiring specialized staff could quickly impact profitability.

Regulatory and policy changes also pose risks. The company’s expansion strategy depends on favorable state policies, such as the repeal of Certificate of Need laws. Any new regulations that restrict hospital capacity or change reimbursement rates could affect the economics of new facilities. Additionally, federal initiatives like the TEAM model introduce uncertainty around patient flow and payment structures, requiring the company to remain adaptable.

Ultimately, while Encompass Health’s competitive advantages are strong, they are not immune to external pressures. Investors must consider whether the current valuation adequately reflects these risks or if they are temporary obstacles that the company’s fundamentals can overcome.

Key Catalysts and Areas to Monitor

The investment case for Encompass Health now depends on several critical catalysts. The company’s plan to add 500 to 600 beds per year through new and smaller hospitals must translate into sustained patient volume growth. Discharge growth is the key metric to watch; in 2025, the company achieved a 6% increase. Maintaining this momentum, especially after the impact of unit closures in early 2026, will be crucial for validating its market position.

Another important catalyst is the partnership with Palantir, which aims to streamline operations and improve documentation. Success in this area could further reduce labor costs and enhance margins, building on the efficiency gains already achieved.

Financially, the company’s 2026 outlook is a key benchmark. Management targets approximately $825 million in free cash flow, which must support both growth investments and shareholder returns. Falling short of this target could strain the company’s capital allocation strategy and raise questions about the sustainability of its growth plan.

Finally, the company’s geographic expansion into states like North Carolina and Tennessee, with a focus on smaller hospitals by 2027, will test its ability to replicate its operational model in new markets. Success will depend on favorable regulatory environments and continued execution on core growth metrics. For now, maintaining discharge growth and meeting free cash flow guidance are the milestones that will determine whether the current valuation is justified or if risks remain underappreciated by the market.